Trial Profile
A Multi-Center, Open Label, Dose-Area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Adverse reactions
- Sponsors Peplin
- 11 Apr 2013 New trial record
- 12 Mar 2013 Results presented at the 71st Annual Meeting of the American Academy of Dermatology.